No products in the cart.
Rabbit polyclonal ISG15 antibody (A1182)
Supplier: ABclonal Inc.
Recommended applications: WB,IHC
WB 1:500 – 1:2000 IHC 1:50 – 1:200
Recommended protocols: check protocols
Click or hover above images to see image description for Rabbit polyclonal ISG15 antibody.
Check alternative names for the antibodyExpand
ISG15 antibody,G1P2 antibody,IFI15 antibody,UCRP antibody
G1P2 antibody|hUCRP antibody|IFI 15 antibody|IFI15 antibody|Interferon alpha inducible protein antibody|Interferon induced protein 15 antibody|Interferon induced protein IFI-15K antibody|Interferon stimulated protein 15 kDa antibody|Interferon, alpha-inducible protein (clone IFI-15K) antibody|Interferon-induced 15 kDa protein antibody|Interferon-induced 17 kDa protein antibody|Interferon-induced 17-kDa/15-kDa protein antibody|IP17 antibody|ISG 15 antibody|ISG15 antibody|ISG15 ubiquitin like modifier antibody|ISG15_HUMAN antibody|Ubiquitin cross-reactive protein antibody|Ubiquitin-like protein ISG15 antibody|UCRP antibody|Anti-ISG15 antibody [EPR3445] (ab92345)
SCBT cat No: sc-69701|sc-514964|sc-166712|sc-166755|sc-50366|sc-323987|
Rabbit polyclonal ISG15 antibody
|Catalogue No.|| |
Recombinant protein of human ISG15
|Recommended dilution|| |
WB 1:500 – 1:2000
|Molecular weight|| |
Predicted: 18kDa/Observed: Refer to Figures
ISG15 antibody was tube-contained.
ISG15 antibody was purified using affinity purification.
Store at -20 Celsius degree. Avoid freeze / thaw cycles.
|Alternative antibody names|| |
ISG15 antibody,G1P2 antibody,IFI15 antibody,UCRP antibody
|Database links|| |
|Protein names|| |
|Protein function|| |
Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation-inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA-induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity.
|Protein tissue specificity|| |
Detected in lymphoid cells, striated and smooth muscle, several epithelia and neurons. Expressed in neutrophils, monocytes and lymphocytes. Enhanced expression seen in pancreatic adenocarcinoma, endometrial cancer, and bladder cancer, as compared to non-cancerous tissue. In bladder cancer, the increase in expression exhibits a striking positive correlation with more advanced stages of the disease.
|Protein sequence and domain|| |
Both the Ubiquitin-like 1 and Ubiquitin-like 2 domains are required for its efficient conjugation to cellular proteins. The two domains play different roles in the ISGylation pathway: Ubiquitin-like 2 domain is necessary for the first two steps allowing the linking of ISG15 to the E1 and E2 enzymes while Ubiquitin-like 1 domain is essential for the final, E3-mediated transfer of ISG15, from the E2 to the Lys of the target protein .Contains 2 ubiquitin-like domains.
|Protein post-translational modifications|| |
S-nitrosylation decreases its dimerization, thereby increasing the availability as well as the solubility of monomeric ISG15 for its conjugation to cellular proteins.; Induced as an inactive, precursor protein that is cleaved by specific proteases to expose the C-terminal diglycine (LRLRGG) motif. This motif is essential not only for its conjugation to substrates but also for its recognition by the relevant processing proteases.
|Protein cellular localization|| |
Cytoplasm . Secreted . Note: Exists in three distinct states: free within the cell, released into the extracellular space, or conjugated to target proteins.
Interferon-stimulated 15 kDa protein (ISG15), also known as ubiquitin cross-reactive protein (UCRP), is a member of the ubiquitin-like protein family and functions in various biological pathways from pregnancy to innate immune responses (1). Expression of ISG15 is stimulated by cellular exposure to type 1 interferons alpha and beta, in addition to infection with viruses such as influenza B (2,3). After exposure to type I interferons, both lymphocytes and monocytes, in addition to some fibroblasts and epithelial cells, release ISG15 into culture medium (1,4). ISG15 has been shown to function as a cytokine, stimulating interferon gamma secretion by monocytes and macrophages, proliferation of natural killer cells, and chemotactic responses in neutrophils (4,5). ISG15 has also been shown to function intracellularly, being covalently conjugated to other proteins by E1 (Ube1L), E2 (UbcH8) and E3 ligases via a multi-step process analogous to ubiquitination (6,7). ISG15 is removed from proteins by the ubiquitin processing protease Ubp43 (8). ISG15-protein conjugation (ISGylation) is induced by type 1 interferons, and target proteins include the serine protease inhibitor Serpin 2A, PLCgamma1, ERK1/2, Jak1 and Stat1 (9,10). Unlike ubiquitination, ISGylation does not target proteins for degradation, rather ISGylation increases Jak1 and Stat1 activity, enhancing the cellular response to interferons (11).
AntibodyPlus can customize ISG15 antibody according to your requirement, including bulk product size,etc. Please contact email@example.com. AntibodyPlus provides antibody trial sample for your own antibody validation.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: